- Home
- SLXN vs EVAX Comparison
SLXN vs EVAX Comparison
Compare SLXN & EVAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SLXN
- EVAX
- Stock Information
- Founded
- SLXN 2008
- EVAX 2008
- Country
- SLXN Israel
- EVAX Denmark
- Employees
- SLXN N/A
- EVAX N/A
- Industry
- SLXN
- EVAX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- SLXN
- EVAX Health Care
- Exchange
- SLXN NYSE
- EVAX Nasdaq
- Market Cap
- SLXN 7.3M
- EVAX 10.8M
- IPO Year
- SLXN N/A
- EVAX 2021
- Fundamental
- Price
- SLXN $0.81
- EVAX $2.45
- Analyst Decision
- SLXN Strong Buy
- EVAX Strong Buy
- Analyst Count
- SLXN 1
- EVAX 2
- Target Price
- SLXN $5.00
- EVAX $10.00
- AVG Volume (30 Days)
- SLXN 147.1K
- EVAX 115.3K
- Earning Date
- SLXN 08-21-2025
- EVAX 08-13-2025
- Dividend Yield
- SLXN N/A
- EVAX N/A
- EPS Growth
- SLXN N/A
- EVAX N/A
- EPS
- SLXN N/A
- EVAX N/A
- Revenue
- SLXN N/A
- EVAX $3,293,000.00
- Revenue This Year
- SLXN N/A
- EVAX N/A
- Revenue Next Year
- SLXN N/A
- EVAX N/A
- P/E Ratio
- SLXN N/A
- EVAX N/A
- Revenue Growth
- SLXN N/A
- EVAX 2555.64
- 52 Week Low
- SLXN $0.58
- EVAX $1.20
- 52 Week High
- SLXN $41.85
- EVAX $17.75
- Technical
- Relative Strength Index (RSI)
- SLXN N/A
- EVAX 50.23
- Support Level
- SLXN N/A
- EVAX $2.35
- Resistance Level
- SLXN N/A
- EVAX $2.60
- Average True Range (ATR)
- SLXN 0.00
- EVAX 0.27
- MACD
- SLXN 0.00
- EVAX -0.05
- Stochastic Oscillator
- SLXN 0.00
- EVAX 34.35
About SLXN BIOMOTION SCIENCES
Silexion Therapeutics Corp a clinical-stage, oncology-focused biotechnology company engaged in the discovery and development of proprietary treatments for KRAS-driven cancers. The KRAS gene is an oncogene that is involved in the regulation of cell division as a result of its ability to relay external signals into the cell. Its product candidate, SIL204, consists of locally administered small interfering RNAs, or siRNA, in a solution, as a first-line treatment of locally advanced pancreatic cancer patients, or LAPC, in combination with standard-of-care chemotherapy. It is currently focused on treatment for pancreatic cancer tumors bearing the KRAS G12D or KRAS G12V mutations where metastases have not been detected and are non-resectable, i.e. it is not able to be surgically removed.
About EVAX Evaxion Biotech
Evaxion AS is in the field of oncology. It used the AI-Immunology platform.